You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) s

    SBC: Caladrius Biosciences            Topic: NIAID

    DESCRIPTION (provided by applicant): In the event of a nuclear accident or terrorist bomb, large numbers of casualties will have been exposed to acute high-dose radiation. Those exposed will have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. A compromised immune system exacerbates the effects of infectious agents and may preclu ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Point-of-care detection for nanoparticle-based sensors

    SBC: JUNCO LABS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Although nanomaterials have tremendous potential to improve human health, it has remained surprisingly elusive to leverage their properties to produce real clinical impact. One of the most promising applications of nanoparticles is in sensors for detection of analytes. For sensors that need to be performed at the point of care (POC), one large barrier to unlock ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease is the most common vector borne infectious disease in North America and Europe. It is a progressive disease with a wide array of clinical manifestations. Treatment of early infection is highly effective, and early diagnosis and treatment are critical to prevent disease progression. By contrast, disseminated late- phase infection is associated with ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD

    SBC: CERAMIDE THERAPEUTICS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Acute graft-versus-host disease (GvHD) is a primary complication of allogeneic stem cell transplantation, associated with wasting, immunosuppression and specific damage to the intestines, liver and skin. GvHD results from activation of donor T cells from human leukocyte antigen (HLA)-identical or related donors against host tissues. Current therapeutic approac ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognos ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Retinoic Acid Modulation for Scleroderma

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) or diffuse scleroderma is a complex, chronic, autoimmune, connective tissue disease which primarily causes skin thickening and hardening in addition to interstitial fibrosis of lungs, gastrointestinal tract and arteries. Estimates of the prevalence of SSc in the United States (US) range from 140 to 276 patients per million (or 49,000 to ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Human Adipocyte Platform for Discovery of Novel Adiponectin Secretagogues

    SBC: DISCOVERYBIOMED, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Small business concerns, DiscoveryBioMed, Inc. (DBM) and Chromadex, Inc. (CDex), have designed an innovative automation-friendly drug discovery program to screen medicinal plant-derived phytochemicals and extract fractions on an immortalized human adipocyte platform to discover novel, selective secretagogues of adiponectin, an established biomarker and causativ ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. An agent for the treatment of lung cancer

    SBC: Medicon            Topic: NCI

    DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the US and worldwide. Given its prevalence, morbidity and mortality, it is clear that in terms of treatment, the lung cancer problem is far from solved; and thatnew agents are urgently needed. Our preliminary data indicate that the novel compound phospho-sulindac (PS) is potentially highly effective agai ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Quantitative ultrasound analysis of vascular morphology for cancer assessment

    SBC: KITWARE INC            Topic: NCI

    DESCRIPTION (provided by applicant): There are several features of ultrasound as an imaging modality that make it attractive to clinicians and preclinical researchers today, including its relatively low cost, real-time imaging capability, safety, and portability. These facets make it a particularly accessible imaging technique for rural and lower-income communities, and thus ultrasonic diagnostic ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Schiff base forming sunscreen filters for long-wear UV protection

    SBC: NANOMETICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Problem to be solved: Skin cancer is the most common of all cancers, accounting for nearly half of all reported cancer cases in the USA. According to the American Cancer Society (ACS), the best way to lower the risk ofnon-melanoma skin cancer is to practice sun safety by applying broad-spectrum sunscreens. One major disadvantage of commercial sunscreens is ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government